Navigation Links
Idenix Pharmaceuticals Reports First Quarter Financial Results
Date:4/30/2009

direct-acting HCV antivirals, we have made substantial progress toward achieving this goal."

For the first quarter ended March 31, 2009, Idenix reported total revenues of $4.0 million, compared with total revenues of $2.0 million in the first quarter of 2008. Idenix reported a net loss of $12.9 million, or a loss of $0.23 per basic and diluted share, for the first quarter ended March 31, 2009, compared to a net loss of $20.5 million, or a loss of $0.36 per basic and diluted share for the first quarter ended March 31, 2008.

2009 Financial Guidance

The company continues to expect that its current cash, cash equivalents and marketable securities can fund operations through at least the first quarter of 2010. This guidance assumes no milestone payments, additional license fees, reimbursement for development programs and no financing activities during 2009.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of hepatitis C virus. For further information about Idenix, please refer to www.idenix.com.

Forward-looking Statements

This press release contains "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified by the use of forward-looking terminology such as "expect," "plans," "anticipates," "will," "expects," "goal" or similar expressions, or by express or implied statements with respect to the company's clinical development programs or commercialization activities in HIV or hepatitis C, or any potential pipeline candidates, including any expressed or implied statements regarding the efficacy and safety of IDX1
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
2. Idenix to Host Conference Call Discussing Third Quarter 2007 Financial Results
3. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
4. Idenix to Host Conference Call Discussing Fourth Quarter 2007 Financial Results
5. Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL)
6. Idenix Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. Idenix Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Idenix Pharmaceuticals to Present at the Seventh Annual Needham and Company, LLC Biotechnology and Medical Technology Conference
9. Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results
10. Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
11. Idenix to Host Conference Call Discussing Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Wash. , Dec. 24, 2014   BioLife ... leading developer, manufacturer and marketer of proprietary clinical grade ... media and precision thermal shipping products for ... that it will hold its 2015 Annual Meeting of ... Because the expected date for the Annual Meeting ...
(Date:12/24/2014)... 23, 2014 On Friday, December ... 83, the Omnibus and Continuing Resolution Appropriations Act ... hydrocephalus a condition eligible to receive funding through ... by the Department of Defense (DoD). The Hydrocephalus ... on Capitol Hill, is celebrating this victory for ...
(Date:12/24/2014)... December 23, 2014 Pipette.com announces their ... Twitter followers can submit their #HolidayInTheLab pictures for a ... lab mates. , For those struggling to think of ... Pipette.com Holiday in the Lab Contest provides the ideal ... followers to send pictures of their chemistree, holiday ...
(Date:12/24/2014)... , Dec. 23, 2014  Rock Creek Pharmaceuticals, ... it has filed a Clinical Trial Application (CTA) with ... products Regulatory Agency (MHRA) seeking regulatory approval to initiate ... molecule, Anatabine Citrate. Contingent on the Company ... a Phase I trial to assess the safety, tolerability ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... that do not specialize in software, but incorporate software-based ... more often than not, overlook the importance of protecting ... feature or the most prevalent feature of the product, ... and should be protected. , ,For example, many ...
... MADISON Health statistics are often broken down into categories ... meaningless concept that has no basis in biology or genetics. ... at a symposium titled Race, Genetics & Disease at Grainger ... Holtz Center for Science and Technology Studies sponsored the ...
... compete for $22,000 in awards this Friday as part ... Plan Competition . Fourteen teams of aspiring student entrepreneurs, ... their plans for technology-based businesses to a panel of ... UW System, this competition is the only activity on ...
Cached Biology Technology:Beyond the screws and gears: Protecting your products by protecting your software 2Symposium examines the effect of race on genetics and disease 2Students compete for $22,000 in Tech Business Plan Competition 2Students compete for $22,000 in Tech Business Plan Competition 3
(Date:12/10/2014)... DIEGO , Dec. 9, 2014 CIE ... collaboration catalyst that provides the connective tissue that enhances ... enabling them to easily share client-level information; earned a ... to expand to organizations serving seniors aging in community ... Diego" partner on December 11 th 4-6p. ...
(Date:12/10/2014)... 2014     ...   Jifflenow, a leading ... for business-to-business (B2B) events, today announced a partnership ... near-field communication (NFC), Bluetooth low energy (BLE), and ... , Jifflenow will integrate its meeting ...
(Date:12/5/2014)... Utah , Dec. 4, 2014  Tute Genomics, ... raised $2.3 million in Series A1 funding led by ... investors also participated in the investment round. ... the healthcare community adopts next-generation sequencing and seeks new ... said Reid Robison , MD MBA, and CEO ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... to investigate how lethal viruses attack differently sized populations of ... to new methods of pest control. The project, funded by ... meal moth ( Plodia interpunctella ) and a virus it ... not. Dr Steve Sait from the University of Leeds ...
... Something strange happened in 1973. Republican president Richard Nixon -- ... the land of quotas and restrictions" -- signed the Endangered ... about ecological issues -- and the rapid decline of charismatic ... to pass the law 92-0. Sounding more Thoreauvian than Thatcherite, ...
... boat owner recognises the dilemma: environmentally friendly or effective. ... a way of reconciling these two almost unattainable aims. ... biocides in the paint, it is possible to both ... the environmental impact. "It,s very easy to make ...
Cached Biology News:No safety in numbers for moths and butterflies 2Dispatches from the edge of doom 2Dispatches from the edge of doom 3Dispatches from the edge of doom 4More effective and less risky when you paint the hull of your boat 2
... Custom design, The Bioactive peptides are ... display a biological behaviour or activity which ... for pharmaceutical, diagnostic, chemical and agro-food applications. ... obtain modified peptides with superior properties for ...
... This CLS number is a ... easily match Cornings product number. ... please order under the old ... customer service for assistance. ...
... with forced convection Temperature range 5 C ... C / 212 F Patented APT.line preheating ... DS controller Timer 0 to 24 h ... a tenth of a degree Independent adjustable ...
... your microarray data using Asuragens bioinformatics ... need from consultation to extensive data ... date methods. Utilize our expertise in ... Service or from your own microarray ...
Biology Products: